OYST News and Press, Oyster Point Pharma Inc. From 08/07/20

Oyster Point Pharma, Inc. (OYST) Q2 2020 Earnings Conference Call August 05, 2020 08:30 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jeffrey Nau – President & Chief Executive Officer John Snisarenko – Chief Commercial Officer Con...

Image source: The Motley Fool. Oyster Point Pharma, Inc.   (NASDAQ: OYST) Q2 2020 Earnings Call Aug 05, 2020 , 8:30 a.m. ET Operator Continue reading

Oyster Point Pharma (NASDAQ: OYST ) : Q2 GAAP EPS of -$0.66 beats by $0.15 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020 Cash and Cash Equivalents of $226.7 million as of June 30, 2020 Conference Call and Webcast Scheduled for 8:30 am ET today...

PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

Developing novel drugs for unmet medical needs remains the mission for many emerging drug developers. These pharma companies tackle a range of diseases but have one common attribute. Healthcare investors can look past the development risk. Two companies have approved drugs recently launched in...

PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the closing of a p...

Cassava Sciences (NASDAQ: SAVA )  -82%  after Alzheimer's candidate flunks mid-stage study. More news on: Cassava Sciences, Inc., Synthesis Energy Systems, Inc., Creative Realities, Inc., Stocks on the move, , Read more ...

Oyster Point Pharma (NASDAQ: OYST ) has priced its public offering of 3.75M common shares at $28.00/share, for expected gross proceeds of $105M. More news on: Oyster Point Pharma, Inc., Healthcare stocks news, Read more ...

PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its...